The Effectiveness of Covid-19 Vaccination in Indonesian Population: A Case-Control Study Protocol

DOI

10.2991/978-94-6463-112-8_71How to use a DOI?

Keywords

Indonesia; COVID-19 vaccine; effectiveness; symptomatic COVID-19

Abstract

It is essential to prove a vaccination program's effectiveness before initiating such a program to the entire population. Accordingly, the government of Indonesia has conducted research at the beginning of the COVID-19 vaccination program. The general objective of the current study was to assess the effectiveness of COVID-19 vaccine against symptomatic COVID-19 incidence and its severity. This is a protocol study of an unmatched case-control study design. The subjects are health workers and members of the community. The case group is symptomatic COVID-19 as confirmed by the RT PCR or Antigen rapid tests taken during the data collection time on 13 January 2021 for the health workers and in February 2021 for non-health workers. Meanwhile, the control group consisted of people who are at least 18 years old and had never been diagnosed with COVID-19. The ratio of cases and controls in the health workers group is 1:4, while the ratio for the community group is 1:1. Based on the previous effectiveness study, the city of Bandung required 4625 health workers and 3834 non-health workers. The data for the study were collected from July to October 2021 in seven provinces and 14 districts/cities. The case group data were obtained from hospital medical records, while the control group data were collected from the same hospital and community living in areas heavily affected by COVID-19. Trained enumerators filled out the patient questionnaires, while the control group filled out the questionnaires themselves. The degree of severity of COVID-19 was obtained from the doctor in charge of the patients (DPJP). This study used the Lime Survey application from the link http://bit.ly/effectiveness_vaksin_c19. Data analysis was carried out separately for the groups of health workers and community groups. We calculated the odds ratio (OR) adjusted by age, gender, and comorbid diseases; then the effectiveness of the vaccination was designated as 1-OR. Vaccine effectiveness will be calculated based on the type of vaccine as well. The Indonesian government will use the results as scientific evidence of the effectiveness of COVID-19 vaccination in Indonesia.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Sri Idaiani
AU  - Nurhayati Nurhayati
AU  - Delima Delima
AU  - Harimat Hendarwan
AU  - Lucie Widowati
AU  - Ingan U. Tarigan
AU  - Nurfi Afriansyah
AU  - Sundari Wirasmi
AU  - Diah Yunitawati
AU  - Setyo Adiningsih
AU  - Hadjar Siswantoro
AU  - Tince A. Jovina
AU  - Yenni Risniati
AU  - Rossa Avrina
AU  - Armaji K. Syarif
AU  - Nita Prihartini
AU  - Narendro Arifia
AU  - Yusi D. Nurcahyani
AU  - Evi I. Natalia
AU  - Made D. Susilawati
AU  - Jarir A. Thobari
PY  - 2023
DA  - 2023/03/01
TI  - The Effectiveness of Covid-19 Vaccination in Indonesian Population: A Case-Control Study Protocol
BT  - Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)
PB  - Atlantis Press
SP  - 785
EP  - 795
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-112-8_71
DO  - 10.2991/978-94-6463-112-8_71
ID  - Idaiani2023
ER  -